We are live on
!
Find out more
SCM
Stonepine Capital Management Portfolio holdings
AUM
$250M
1-Year Est. Return
77.6%
This Fund
S&P 500
This Quarter
Est. Return
+20.81%
1 Year Est. Return
+77.6%
3 Year Est. Return
+198.76%
5 Year Est. Return
+226.15%
10 Year Est. Return
+1,976.54%
AUM
$137M
AUM Growth
+$14M
(+11%)
Cap. Flow
+$285M
Cap. Flow
% of AUM
208.33%
Top 10 Holdings %
Top 10 Hldgs %
53.02%
Holding
89
New
31
Increased
13
Reduced
18
Closed
23
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
RADX
Radiopharm Theranostics
RADX
|
+$272M |
| 2 |
Corbus Pharmaceuticals
CRBP
|
+$4.81M |
| 3 |
KZIA
Kazia Therapeutics
KZIA
|
+$3.92M |
| 4 |
Inhibikase Therapeutics
IKT
|
+$2.57M |
| 5 |
Adicet Bio
ACET
|
+$2.43M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
DAWN
Day One Biopharmaceuticals
DAWN
|
+$3.74M |
| 2 |
Enanta Pharmaceuticals
ENTA
|
+$2.6M |
| 3 |
OmniAb
OABI
|
+$2.51M |
| 4 |
Zevra Therapeutics
ZVRA
|
+$2.28M |
| 5 |
Surrozen
SRZN
|
+$2.21M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 92.31% |
| 2 | Financials | 0% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
76
Health Catalyst
HCAT
$163M
| – | – |
-155,551
| Closed | -$443K |
|
77
Solana Company
HSDT
$98.1M
| – | – |
-20,000
| Closed | -$298K |
|
78
Jasper Therapeutics
JSPR
$20.2M
| – | – |
-20,200
| Closed | -$48.1K |
|
79
Larimar Therapeutics
LRMR
$413M
| – | – |
-25,000
| Closed | -$80.8K |
|
80
Ultragenyx Pharmaceutical
RARE
$2.46B
| – | – |
-20,000
| Closed | -$658K |
|
81
Rezolute
RZLT
$473M
| – | – |
-40,000
| Closed | -$376K |
|
|
SLNO
82
DELISTED
Soleno Therapeutics
SLNO
| – | – |
-24,000
| Closed | -$1.62M |
|
83
Syndax Pharmaceuticals
SNDX
$1.7B
| – | – |
-37,200
| Closed | -$572K |
|
84
Savara
SVRA
$1.09B
| – | – |
-60,000
| Closed | -$214K |
|
85
Vir Biotechnology
VIR
$1.5B
| – | – |
-160,000
| Closed | -$914K |
|
86
Vanda Pharmaceuticals
VNDA
$315M
| – | – |
-195,000
| Closed | -$973K |
|
|
ALMS
87
Alumis Inc
ALMS
$3.33B
| – | – |
-300,000
| Closed | -$1.2M |
|
|
GRCE
88
Grace Therapeutics
GRCE
$33.8M
| – | – |
-211,010
| Closed | -$628K |
|
|
WHWK
89
Whitehawk Therapeutics
WHWK
$196M
| – | – |
-35,253
| Closed | -$67K |
|
Similar funds
ER
FDDB
VM
SCM
CWM
EWM
RA
TAM
Stonepine Capital Management's Q4 2025 Portfolio in Review
As of Q4 2025, Stonepine Capital Management held 89 positions worth $137M, up 11% from $123M the previous quarter. Its ten largest holdings account for 53% of the portfolio.
Stonepine Capital Management deployed $285M of net new capital in Q4 2025, opening 31 new positions and adding to 13 existing holdings. Its largest new stake was Radiopharm Theranostics: 51,000,000 shares worth $851K.
By sector, the portfolio is most concentrated in Healthcare at 92% of assets, down from 100% a quarter earlier, followed by Financials.
On the sell side, the largest reduction was Day One Biopharmaceuticals, an estimated $3.74M trimmed.
- Stonepine Capital Management's largest Q4 2025 buy was Radiopharm Theranostics: 51,000,000 shares worth $851K.
- Stonepine Capital Management added most to Inhibikase Therapeutics in Q4 2025, an estimated $2.57M increase.
- Stonepine Capital Management's biggest Q4 2025 reduction was Day One Biopharmaceuticals, cutting an estimated $3.74M.
- Stonepine Capital Management fully exited Soleno Therapeutics in Q4 2025, selling an estimated $1.62M.
- Stonepine Capital Management's ten largest holdings make up 53% of its $137M portfolio in Q4 2025.
- Stonepine Capital Management opened 31 new positions and closed 23 in Q4 2025.
- Stonepine Capital Management's portfolio value rose 11% quarter-over-quarter to $137M.
Based on Stonepine Capital Management's 13F filing for Q4 2025, filed 13 Feb 2026.